Alkem Laboratories ALKEM
Top-5 Indian branded formulations company, strongest in anti-infectives and GI (Clavam, Pan), with a US generics arm and Enzene biologics/CDMO subsidiary
Mapped in 1 theme: Pharmaceuticals.
Where Alkem Laboratories sits in the supply chain
Alkem Laboratories appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › India branded formulations
OperatorOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 12,668 | 12,965 | 14,712 |
| Net profit | 1,811 | 2,215 | 2,351 |
Latest-year revenue ₹14,712 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Leader in acute therapies with very wide doctor and chemist reach
- US generics (~20% of sales) adds diversification with modest concentration
- Enzene subsidiary gives an option on biosimilars and biologics CDMO
Risks
- Acute/anti-infective mix grows slower than chronic and faces NLEM price control
- Enzene still loss-making and needs capital
- Income-tax provisions have hit profit before (FY23) and disputes remain an overhang
Common questions
What does Alkem Laboratories do?
Top-5 Indian branded formulations company, strongest in anti-infectives and GI (Clavam, Pan), with a US generics arm and Enzene biologics/CDMO subsidiary.
Where does Alkem Laboratories sit in the supply chain?
Alkem Laboratories (NSE: ALKEM) is mapped in 1 supply-chain layer: India branded formulations (Pharmaceuticals).
Who are Alkem Laboratories' peers?
In the India branded formulations layer of Pharmaceuticals: Sun Pharmaceutical Industries, Mankind Pharma, Torrent Pharmaceuticals, Abbott India, Eris Lifesciences, Cipla and 4 more.
What is Alkem Laboratories' market cap and valuation?
As of 30 Oct 2026: market cap ₹61,491 Cr, P/E 27.0x, ROCE 21.2%, ROE 18.9%, dividend yield 1.04%.